Paul Tudor Jones Agenus Inc Transaction History

Tudor Investment Corp Et Al

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$1.12 - $1.88 $18,704 - $31,396	-16,700 Reduced 4.26%	375,627 $424,000
Q2 2023 Aug 14, 2023	SELL	$1.31 - $2.04 $31,886 - $49,655	-24,341 Reduced 5.84%	392,327 $627,000
Q1 2023 May 15, 2023	BUY	$1.45 - $2.95 $111,787 - $227,430	77,095 Added 22.7%	416,668 $633,000
Q4 2022 Feb 14, 2023	BUY	$2.02 - $3.25 $685,937 - $1.1 Million	339,573 New	339,573 $815,000
Q2 2022 Aug 15, 2022	BUY	$1.3 - $2.64 $29,364 - $59,632	22,588 Added 164.0%	36,361 $71,000
Q1 2022 May 16, 2022	SELL	$2.35 - $3.47 $665,454 - $982,606	-283,172 Reduced 95.36%	13,773 $34,000
Q4 2021 Feb 14, 2022	SELL	$2.92 - $5.74 $499,906 - $982,693	-171,201 Reduced 36.57%	296,945 $956,000
Q3 2021 Nov 15, 2021	BUY	$4.98 - $6.63 $2.25 Million - $2.99 Million	451,309 Added 2680.46%	468,146 $2.46 Million
Q2 2021 Aug 16, 2021	SELL	$2.56 - $5.49 $512,038 - $1.1 Million	-200,015 Reduced 92.24%	16,837 $92,000
Q1 2021 May 17, 2021	BUY	$2.69 - $5.25 $583,331 - $1.14 Million	216,852 New	216,852 $590,000
Q3 2020 Nov 16, 2020	SELL	$2.98 - $5.2 $45,099 - $78,696	-15,134 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$2.29 - $4.24 $34,656 - $64,168	15,134 New	15,134 $59,000
Q3 2018 Nov 14, 2018	SELL	$1.59 - $2.42 $30,314 - $46,139	-19,066 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.26 - $4.65 $43,089 - $88,656	19,066 New	19,066 $43,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.